Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease

Molecular Oncology

Volumn 10, Issue 5, 2016, Pages 677-692

  Potratz, Jenny ^a   Tillmanns, Amelie ^a   Berning, Philipp ^a   Korsching, Eberhard ^b   Schaefer, Christiane ^a   Lechtape, Birgit ^a   Schleithoff, Carolin ^a   Unland, Rebekka ^a   Schäfer, Karl Ludwig ^c   Müller Tidow, Carsten ^d   Jürgens, Heribert ^a   Dirksen, Uta ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Institute of Pathology   (Germany)

^d MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Ewing sarcoma; Metastasis; Receptor tyrosine kinase; ROR1; Therapeutic target

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; PROTEIN VARIANT; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; SMALL INTERFERING RNA; TIE 1 RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; WNT5A PROTEIN; ROR1 PROTEIN, HUMAN; TRANSCRIPTOME; WNT5A PROTEIN, HUMAN;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EWING SARCOMA; EWING SARCOMA CELL LINE; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; METASTASIS; METASTASIS INHIBITION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SCHOOL CHILD; SIGNAL TRANSDUCTION; BONE; BONE NEOPLASMS; CELL MOTION; GENETICS; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; RNAI THERAPEUTICS; SARCOMA, EWING; TUMOR CELL LINE;

ADOLESCENT; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; SARCOMA, EWING; TRANSCRIPTOME; WNT-5A PROTEIN;

EID: 84953290336     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.12.009     Document Type: Article

References (72)

1. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
2. Baskar S., Kwong K.Y., Hofer T., Levy J.M., Kennedy M.G., Lee E., Staudt L.M., Wilson W.H., Wiestner A., Rader C. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 2008, 14:396-404.
3. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodological) 1995, 57:289-300.
4. Bernstein M., Kovar H., Paulussen M., Randall R.L., Schuck A., Teot L.A., Juergens H. Ewing's sarcoma family of tumors: current management. Oncologist 2006, 11:503-519.
5. Bicocca V.T., Chang B.H., Masouleh B.K., Muschen M., Loriaux M.M., Druker B.J., Tyner J.W. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012, 22:656-667.
6. Bozzi F., Tamborini E., Negri T., Pastore E., Ferrari A., Luksch R., Casanova M., Pierotti M.A., Bellani F.F., Pilotti S. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. Cancer 2007, 109:1638-1645.
7. Bryja V., Schulte G., Rawal N., Grahn A., Arenas E. Wnt-5a induces Dishevelled phosphorylation and dopaminergic differentiation via a CK1-dependent mechanism. J. Cel. Sci. 2007, 120:586-595.
8. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002, 62:200-207.
9. Chugh R., Wathen J.K., Maki R.G., Benjamin R.S., Patel S.R., Meyers P.A., Myers P.A., Priebat D.A., Reinke D.K., Thomas D.G., Keohan M.L., Samuels B.L., Baker L.H. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J. Clin. Oncol. 2009, 27:3148-3153.
10. Cotterill S.J., Ahrens S., Paulussen M., Jürgens H.F., VoÛte P.A., Gadner H., Craft A.W. Prognostic factors in Ewing"s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing"s Sarcoma Study Group. J. Clin. Oncol. 2000, 18:3108-3114.
11. Cui B., Zhang S., Chen L., Yu J., Widhopf G.F., Fecteau J.-F., Rassenti L.Z., Kipps T.J. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013, 73:3649-3660.
12. Dalal S., Berry A.M., Cullinane C.J., Mangham D.C., Grimer R., Lewis I.J., Johnston C., Laurence V., Burchill S.A. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin. Cancer Res. 2005, 11:2364-2378.
13. Dave H., Anver M.R., Butcher D.O., Brown P., Khan J., Wayne A.S., Baskar S., Rader C. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS ONE 2012, 7:e52655.
14. Desbois-Mouthon C., Baron A., Blivet-Van Eggelpoël M.-J., Fartoux L., Venot C., Bladt F., Housset C., Rosmorduc O. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin. Cancer Res. 2009, 15:5445-5456.
15. Do I., Araujo E.S., Kalil R.K., Bacchini P., Bertoni F., Unni K.K., Park Y.-K. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Pathol. Res. Pract. 2007, 203:127-134.
16. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.-M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Jänne P.A. MET amplification leads to Gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
17. Ern C., Krump-Konvalinkova V., Docheva D., Schindler S., Rossmann O., Böcker W., Mutschler W., Schieker M. Interactions of human endothelial and multipotent mesenchymal stem cells in cocultures. Open Biomed. Eng. J. 2010, 4:190-198.
18. Fukuda T., Chen L., Endo T., Tang L., Lu D., Castro J.E., Widhopf G.F., Rassenti L.Z., Cantwell M.J., Prussak C.E., Carson D.A., Kipps T.J. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. U.S.A 2008, 105:3047-3052.
19. Gentile A., Lazzari L., Benvenuti S., Trusolino L., Comoglio P.M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 2011, 71:3132-3141.
20. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 2004, 4:361-370.
21. Gurney J.G., Swensen A.R., Bulterys M. Malignant bone tumors. Cancer Incidence and Survival Among Children and Adolescents 1999, 99-110. L. Ries, M.A. Smith, J.G. Gurney (Eds.).
22. Haeusler J., Ranft A., Boelling T., Gosheger G., Braun-Munzinger G., Vieth V., Burdach S., van den Berg H., Juergens H., Dirksen U. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010, 116:443-450.
23. Hojjat-Farsangi M., Khan A.S., Daneshmanesh A.H., Moshfegh A., Sandin A., Mansouri L., Palma M., Lundin J., Österborg A., Mellstedt H. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS ONE 2013, 8:e78339.
24. Hojjat-Farsangi M., Moshfegh A., Daneshmanesh A.H., Khan A.S., Mikaelsson E., Österborg A., Mellstedt H. The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy. Semin. Cancer Biol. 2014, 29C:21-31.
25. Huang F., Hurlburt W., Greer A., Reeves K.A., Hillerman S., Chang H., Fargnoli J., Graf Finckenstein F., Gottardis M.M., Carboni J.M. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res. 2010, 70:7221-7231.
26. Huang J., Bae J.-O., Tsai J.P., Kadenhe-Chiweshe A., Papa J., Lee A., Zeng S., Kornfeld Z.N., Ullner P., Zaghloul N., Ioffe E., Nandor S., Burova E., Holash J., Thurston G., Rudge J., Yancopoulos G.D., Yamashiro D.J., Kandel J.J. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int. J. Oncol. 2009, 34:79-87.
27. Huang X., Park H., Greene J., Pao J., Mulvey E., Zhou S.X., Albert C.M., Moy F., Sachdev D., Yee D., Rader C., Hamby C.V., Loeb D.M., Cairo M.S., Zhou X. IGF1R- and ROR1-specific CAR t cells as a potential therapy for high risk sarcomas. PLoS One 2015, 10:e0133152.
28. Janovska P., Poppova L., Plevova K., Plesingerova H., Behal M., Kaucka M., Ovesna P., Hlozkova M., Borsky M., Stehlikova O., Brychtova Y., Doubek M., Machalova M., Baskar S., Kozubik A., Pospisilova S., Pavlova S., Bryja V. Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. Clin. Cancer Res. Clincanres 2015, 0154.2015. 10.1158/1078-0432.CCR-15-0154.
29. Jänne P.A., Gray N., Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 2009, 8:709-723.
30. Jones N., Iljin K., Dumont D.J., Alitalo K. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat. Rev. Mol. Cell Biol. 2001, 2:257-267.
31. Juergens H., Daw N.C., Geoerger B., Ferrari S., Villarroel M., Aerts I., Whelan J., Dirksen U., Hixon M.L., Yin D., Wang T., Green S., Paccagnella L., Gualberto A. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 2011, 29:4534-4540.
32. Jun H.J., Bronson R.T., Charest A. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells 2014, 32:338-348.
33. Kaucká M., Krejčí P., Plevová K., Pavlová S., Procházková J., Janovská P., Valnohová J., Kozubík A., Pospíšilová S., Bryja V. Post-translational modifications regulate signalling by Ror1. Acta Physiol. (Oxf) 2011, 203:351-362.
34. Kreuter M., Paulussen M., Boeckeler J., Gerss J., Buerger H., Liebscher C., Kessler T., Jurgens H., Berdel W.E., Mesters R.M. Clinical significance of vascular endothelial growth Factor-A expression in Ewing's sarcoma. Eur. J. Cancer 2006, 42:1904-1911.
35. Krishnan K., Khanna C., Helman L.J. The biology of metastases in pediatric sarcomas. Cancer J. 2005, 11:306-313.
36. Kurmasheva R.T., Dudkin L., Billups C., Debelenko L.V., Morton C.L., Houghton P.J. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009, 69:7662-7671.
37. Ladenstein R., Pötschger U., Le Deley M.C., Whelan J., Paulussen M., Oberlin O., van den Berg H., Dirksen U., Hjorth L., Michon J., Lewis I., Craft A., Jurgens H. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J. Clin. Oncol. 2010, 28:3284-3291.
38. Le Deley M.C., Paulussen M., Lewis I., Brennan B., Ranft A., Whelan J., Le Teuff G., Michon J., Ladenstein R., Marec-Bérard P., van den Berg H., Hjorth L., Wheatley K., Judson I., Juergens H., Craft A., Oberlin O., Dirksen U. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J. Clin. Oncol. 2014, 32:2440-2448.
39. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
40. Mendoza-Naranjo A., El-Naggar A., Wai D.H., Mistry P., Lazic N., Ayala F.R.R., da Cunha I.W., Rodriguez-Viciana P., Cheng H., Tavares Guerreiro Fregnani J.H., Reynolds P., Arceci R.J., Nicholson A., Triche T.J., Soares F.A., Flanagan A.M., Wang Y.Z., Strauss S.J., Sorensen P.H. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol. Med. 2013, 5:1019-1034.
41. Müller-Tidow C., Diederichs S., Bulk E., Pohle T., Steffen B., Schwäble J., Plewka S., Thomas M., Metzger R., Schneider P.M., Brandts C.H., Berdel W.E., Serve H. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res. 2005, 65:1778-1782.
42. Müller-Tidow C., Schwäble J., Steffen B., Tidow N., Brandt B., Becker K., Schulze-Bahr E., Halfter H., Vogt U., Metzger R., Schneider P.M., Büchner T., Brandts C., Berdel W.E., Serve H. High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin. Cancer Res. 2004, 10:1241-1249.
43. Ohali A., Avigad S., Zaizov R., Ophir R., Horn-Saban S., Cohen I.J., Meller I., Kollender Y., Issakov J., Yaniv I. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004, 23:8997-9006.
44. Olmos D., Tan D.S.W., Jones R.L., Judson I.R. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010, 16:183-194.
45. Pappo A.S., Patel S.R., Crowley J., Reinke D.K., Kuenkele K.-P., Chawla S.P., Toner G.C., Maki R.G., Meyers P.A., Chugh R., Ganjoo K.N., Schuetze S.M., Juergens H., Leahy M.G., Geoerger B., Benjamin R.S., Helman L.J., Baker L.H. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma Alliance for research through Collaboration study. J. Clin. Oncol. 2011, 29:4541-4547.
46. Pasquale E.B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 2010, 10:165-180.
47. Paulussen M., Ahrens S., Burdach S., Craft A., Dockhorn-Dworniczak B., Dunst J., Fröhlich B., Winkelmann W., Zoubek A., Jürgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. Eur. Intergroup Coop. Ewing Sarcoma Stud. Ann. Oncol 1998, 9:275-281.
48. Paulussen M., Craft A.W., Lewis I., Hackshaw A., Douglas C., Dunst J., Schuck A., Winkelmann W., Köhler G., Poremba C., Zoubek A., Ladenstein R., van den Berg H., Hunold A., Cassoni A., Spooner D., Grimer R., Whelan J., McTiernan A., Jürgens H. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J. Clin. Oncol. 2008, 26:4385-4393. European Intergroup Cooperative Ewing's Sarcoma Study-92.
49. Potratz J.C., Saunders D.N., Wai D.H., Ng T.L., McKinney S.E., Carboni J.M., Gottardis M.M., Triche T.J., Jurgens H., Pollak M.N., Aparicio S.A., Sorensen P.H.B. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res. 2010, 70:8770-8781.
50. Riggi N., Suvà M.-L., Suvà D., Cironi L., Provero P., Tercier S., Joseph J.-M., Stehle J.-C., Baumer K., Kindler V., Stamenkovic I. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008, 68:2176-2185.
51. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548-5557.
52. Sáinz-Jaspeado M., Huertas-Martinez J., Lagares-Tena L., Martin Liberal J., Mateo-Lozano S., de Alava E., de Torres C., Mora J., Del Muro X.G., Tirado O.M. EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS ONE 2013, 8:e71449.
53. Schaefer K.-L., Brachwitz K., Braun Y., Diallo R., Wai D.H., Zahn S., Schneider D.T., Kuhnen C., Vollmann A., Brockhoff G., Gabbert H.E., Poremba C. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. Neoplasia 2006, 8:613-622.
54. Schaefer K.-L., Eisenacher M., Braun Y., Brachwitz K., Wai D.H., Dirksen U., Lanvers-Kaminsky C., Juergens H., Herrero D., Stegmaier S., Koscielniak E., Eggert A., Nathrath M., Gosheger G., Schneider D.T., Bury C., Diallo-Danebrock R., Ottaviano L., Gabbert H.E., Poremba C. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur. J. Cancer 2008, 44:699-709.
55. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9:671-675.
56. Shor A.C., Keschman E.A., Lee F.Y., Muro-Cacho C., Letson G.D., Trent J.C., Pledger W.J., Jove R. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 2007, 67:2800-2808.
57. Smith R., Owen L.A., Trem D.J., Wong J.S., Whangbo J.S., Golub T.R., Lessnick S.L. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006, 9:405-416.
58. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 2006, 12:895-904.
59. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., Stegh A.H., Bradner J.E., Ligon K.L., Brennan C., Chin L., DePinho R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
60. Tolcher A.W., Sarantopoulos J., Patnaik A., Papadopoulos K., Lin C.-C., Rodon J., Murphy B., Roth B., McCaffery I., Gorski K.S., Kaiser B., Zhu M., Deng H., Friberg G., Puzanov I. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 2009, 27:5800-5807.
61. Toomey E.C., Schiffman J.D., Lessnick S.L. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 2010, 29:4504-4516.
62. Trivier E., Ganesan T.S. RYK, a catalytically inactive receptor tyrosine kinase, associates with EphB2 and EphB3 but does not interact with AF-6. J. Biol. Chem. 2002, 277:23037-23043.
63. Uren A., Merchant M.S., Sun C.J., Vitolo M.I., Sun Y., Tsokos M., Illei P.B., Ladanyi M., Passaniti A., Mackall C., Toretsky J.A. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003, 22:2334-2342.
64. Uren A., Wolf V., Sun Y.-F., Azari A., Rubin J.S., Toretsky J.A. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr. Blood Cancer 2004, 43:243-249.
65. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
66. Volchenboum S.L., Andrade J., Huang L., Barkauskas D.A., Krailo M., Womer R.B., Ranft A., Potratz J., Dirksen U., Triche T.J., Lawlor E.R. Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour-stromal interactions: a report from the Children's oncology Group. J. Path: Clin. Res. 2015, 1(2):83-94.
67. Whang-Peng J., Triche T.J., Knutsen T., Miser J., Kao-Shan S., Tsai S., Israel M.A. Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet. Cytogenet. 1986, 21:185-208.
68. Yamaguchi T., Yanagisawa K., Sugiyama R., Hosono Y., Shimada Y., Arima C., Kato S., Tomida S., Suzuki M., Osada H., Takahashi T. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012, 21:348-361.
69. Yun J.-H., Lee H.M., Lee E.H., Park J.-W., Cho C.-H. Hypoxia reduces endothelial Ang1-induced Tie2 activity in a Tie1-dependent manner. Biochem. Biophys. Res. Commun. 2013, 436:691-697.
70. Zambelli D., Zuntini M., Nardi F., Manara M.C., Serra M., Landuzzi L., Lollini P.-L., Ferrari S., Alberghini M., Llombart-Bosch A., Piccolo E., Iacobelli S., Picci P., Scotlandi K. Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int. J. Cancer 2010, 126:41-52.
71. Zhang S., Chen L., Cui B., Chuang H.-Y., Yu J., Wang-Rodriguez J., Tang L., Chen G., Basak G.W., Kipps T.J. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 2012, 7:e31127.
72. Zhang S., Chen L., Wang-Rodriguez J., Zhang L., Cui B., Frankel W., Wu R., Kipps T.J. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 2012, 181:1903-1910.